Sobi Q1 2026 report: Strong execution and pipeline momentum

Sobi reported first-quarter 2026 total revenue of SEK 7,184M, up 24% at constant exchange rates and 11% at actual rates versus SEK 6,465M a year ago. Haematology revenue rose 24% at CER to SEK 5,186M, led by Altuvoct sales of SEK 1,240M and Doptelet sales of SEK 1,433M, while Immunology revenue increased 24% at CER to SEK 1,643M on stronger Gamifant and Kineret sales. The update is a solid operating print for a healthcare company, but it is routine earnings reporting without guidance or a major new catalyst.

Analysis

This print looks less like a one-off beat and more like evidence that Sobi’s mix is shifting toward higher-quality, more scalable franchises. The key second-order effect is not just top-line growth, but improved operating leverage: when a biologics portfolio is firing across both hematology and immunology, incremental revenue tends to fall through disproportionately to EBITDA because the commercial infrastructure is already built. That creates a setup where consensus may still be underestimating margin expansion over the next 2-3 quarters, especially if launch momentum persists and gross-to-net pressure stays contained.

The more interesting competitive read is that Sobi appears to be taking share in categories where physician habit and formulary stickiness usually make displacement slow. If Altuvoct and Doptelet continue to scale together, the portfolio can start compounding through cross-prescriber overlap, making it harder for smaller competitors to win back accounts even if they discount. The risk for rivals is not just lost revenue in the quarter, but a rising cost of reacquisition as Sobi’s field force and patient-support infrastructure become more efficient with scale.

The main risk case is that this is still a concentrated growth story: a handful of products are doing most of the work, so any payer pushback, inventory normalization, or slowing new-patient starts could hit sentiment quickly over the next 1-2 quarters. The market may also be underpricing foreign-exchange noise and launch anniversary comps; strong CER growth can still translate into more modest reported growth if FX moves against the name. If the next update shows deceleration in one of the two lead products, the multiple could compress faster than fundamentals because the stock is now set up for perfection.

Contrarian view: the market may be focusing too much on the headline growth rate and not enough on durability of the mix. If these are still early-cycle launches, the real upside is 12-18 months out as penetration deepens and profit conversion improves; if they are already near peak ramp velocity, then the current enthusiasm may be a bit ahead of the data. The right question is whether Sobi is becoming a durable compounder or simply benefiting from a strong launch window that can normalize sooner than bulls expect.

Key Decisions for Investors

• Go long Sobi on a 3-6 month horizon if liquidity allows: the setup favors upward estimate revisions as revenue mix shifts toward launch-led franchises; target a 15-20% upside scenario with downside limited to low-teens multiple compression if growth moderates.
• Use pullbacks to add rather than chase: buy on any 5-8% post-earnings retracement, since the market may initially overreact to reported FX noise while the underlying CER momentum remains intact.
• If you can borrow it, pair long Sobi vs short a slower-growth European specialty pharma basket over the next 1-2 quarters; the trade is about relative estimate revisions and operating leverage, not absolute market direction.
• For risk control, reduce exposure if the next quarterly update shows one lead product slowing materially; that would imply the growth engine is narrower than the current multiple assumes and could cut 10-15% from fair value quickly.
• If options are liquid enough, consider a 3-6 month call spread instead of outright equity to express upside from continued launch momentum while capping premium risk if payer friction emerges.